Ratings PYC Therapeutics Limited

Equities

PYC

AU000000PYC7

Market Closed - Australian S.E. Other stock markets 11:40:14 09/05/2024 am IST			5-day change	1st Jan Change
0.096 ^AUD	-4.00%		-4.00%	-12.73%

03:00am	Transcript : PYC Therapeutics Limited, Q2 2024 Earnings Call, May 09, 2024
22/04	Australian Shares Rebound Amid Easing Middle East Tensions, Ahead of Local Inflation Data	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
PYC THERAPEUTICS LIMITED	-12.73%	307M	-
MODERNA, INC.	+22.56%	46.71B	B-
LONZA GROUP AG	+48.83%	41.8B	A
IQVIA HOLDINGS INC.	-1.51%	41.52B	B
CELLTRION, INC.	-3.42%	29.55B	C
ICON PUBLIC LIMITED COMPANY	+10.13%	25.78B	B-
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.26B	B
BIO-TECHNE CORPORATION	-0.14%	12.14B	B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.08B	C+
MEDPACE HOLDINGS, INC.	+26.45%	11.98B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes